J Mov Disord.  2022 May;15(2):146-150. 10.14802/jmd.21067.

Long-Term Outcome of Hemimasticatory Spasm

• Ray S
• Kamble N
• Yadav R
• Pal PK

• KMID: 2530220
• DOI: http://doi.org/10.14802/jmd.21067

Abstract

Objective
This study aims to identify the demographic, clinical, and therapeutic characteristics of four patients with hemimasticatory spasm (HMS) seen in our outpatient department over a period of 20 years.
Methods
We performed a retrospective chart review of four patients with HMS who visited outpatient services in the Department of Neurology from 2001 to 2020.
Results
The follow-up for all patients ranged from 2 years to 9 years. Three patients had facial or bucco-oral morphea. Two patients maintained long-term improvements in symptoms after being treated with botulinum toxin for 4–7 years, while one patient reported improvement in symptoms with treatment of carbamazepine that subsequently remitted after pregnancy.
Conclusion
This report highlights the long-term outcome of HMS in our patients. Our patients reported a significant reduction or complete resolution of symptoms after treatment, and eventually, two patients were asymptomatic while off treatment.

Keyword

Botulinum toxin; Spasm; Outcome; Morphea